Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald » 07:4702/2102/21/20
After hosting investor…
After hosting investor meetings with Selecta Biosciences (SELB) management, Cantor Fitzgerald analyst Elaina Merle continues to see a high likelihood that the COMPARE study is positive. The shares are positioned for a 50% to 100% plus move up on statistical significance superiority in COMPARE, Merle tells investors in a research note. Selecta's SEL-212 is well powered to show superiority versus Horizon Therapeutics' (HZNP) Krystexxa in the mid-year readout, says the analyst. Further, she sees further optionality from gene therapy, which the company has guided to enter the clinic this year in collaboration with AskBio. Merle reiterates an Overweight rating on Selecta shares with a $10 price target.
Fly Intel: Top five analyst initiations » 10:0702/2002/20/20
EIDX, ITCI, ABUS, HCM, SNDR
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Eidos Therapeutics (EIDX) initiated with a Buy at Guggenheim. 2. Intra-Cellular (ITCI) initiated with an Outperform at Evercore ISI. 3. Arbutus Biopharma (ABUS) initiated with an Outperform at Baird. 4. Hutchison China MediTech (HCM) initiated with a Buy at Goldman Sachs. 5. Schneider National (SNDR) initiated with a Market Perform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Hutchison China MediTech initiated with a Buy at Goldman Sachs » 05:0302/2002/20/20
Goldman Sachs analyst…
Goldman Sachs analyst Paul Choi initiated coverage of Hutchison China MediTech with a Buy rating and $38 price target. The company is on the cusp of a transition that will drive "significant value accretion" over the near-term with key milestones expected in 2020 and 2021, Choi tells investors in a research note. Global partnerships validate the quality of Hutchison's discovery engine, but increasing independence will shape the trajectory from here, he adds.
Enzo Biochem's board increase proposal receives negative recommendation from ISS » 17:2202/1902/19/20
Enzo Biochem shareholders…
Enzo Biochem shareholders Harbert Discovery Fund and Harbert Discovery Co-Investment Fund I, collectively HDF, the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, announced that proxy advisory firm ISS has recommended that shareholders vote against Enzo's proposal to amend its bylaws in order to increase the size of the Board and re-nominate Barry Weiner. Enzo's delayed 2019 Annual Meeting of Shareholders is scheduled for February 25. The analysis from ISS states, among other things: "A deeper review reveals modifications that appear to constitute an eleventh-hour attempt to salvage a board seat for Weiner in light of what appears to be strong shareholder support for the dissident nominees. Given the timing of the announcement - three days before the scheduled Annual General Meeting and after an apparently strong showing of support for the dissident nominees -, the board's assertion that it is somehow shareholder friendly is not only misleading, but arguably deceptive. (...) "The proposed increase in board size appears to be a late-stage entrenchment maneuver in response to what appears to have been robust support for the dissident campaign... (...) Given that it is unclear how this would be a net benefit to shareholders, support AGAINST this proposal is warranted".
Enzo Biochem announces data indicating SK1-I reduced Lupus parameters published » 08:3702/1902/19/20
Enzo Biochem announced…
Enzo Biochem announced the publication of a study in The FASEB Journal by academic researchers that shows drug candidate SK1-I, the company's proprietary Sphingosine Kinase 1 inhibitor, markedly reduced Lupus-associated parameters in a recognized, chemically-induced animal model of Systemic Lupus Erythematosus, commonly known as Lupus. This treatment resulted in reductions in interferon, or IFN, signature, pDC activation and glomerulonephritis, the inflammation of the filtration units of the kidney. Significantly, SK1-I was not only effective when administered simultaneously with the chemical induction of Lupus in this model, but was also effective when administered 30 days after the chemical induction of the disorder. In further confirmation that the effects of SK1-I in the Lupus model are the result of inhibiting the enzyme Sphingosine Kinase 1, the effects were mirrored by genetic deletion of the enzyme. These results suggest that SK1-I may have potential in the treatment of Lupus.
Pulse Biosciences holds a pharmaceutical update conference call » 16:2502/1802/18/20
Management provides an…
Management provides an update on the Company's FDA 510(k) submission for the CellFX System in dermatology on a conference call to be held on February 18 at 5 pm. Webcast Link
Amarin rises as Citi says Buy on selloff, accelerating Vascepa sales » 11:2002/1802/18/20
AMRN, RDY, HKMPF
Shares of Amarin (AMRN)…
Tesla target hikes headline today's top Wall Street calls » 10:3302/1802/18/20
TSLA, AAPL, AMRN, CTL, AEO, M
Check out today's top…
Fly Intel: Top five analyst upgrades » 10:1502/1802/18/20
AMRN, DUK, KN, BC, WWE
Catch up on today's…
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Amarin (AMRN) upgraded to Buy from Neutral at Citi with analyst Joel Beatty saying with the stock trading 27% lower since November, now is an attractive time to buy. 2. Duke Energy (DUK) upgraded to Outperform from Neutral at Credit Suisse with analyst Michael Weinstein sayin he sees last year's $2.5B equity forward that was issued to support any contingency associated with the Atlantic Coast Pipeline project as providing Duke Energy the flexibility to fund additional accretive organic growth in the meantime. 3. Knowles (KN) upgraded to Overweight from Neutral at Piper Sandler with analyst Harsh Kumar saying he expects the operational issues affecting March quarter gross margin and the demand concerns surrounding Chinese handsets to ease entering the June 2020 quarter. 4. Brunswick (BC) upgraded to Outperform from Market Perform at Raymond James with analyst Joseph Altobello saying Brunswick has emerged as the pure-play leader in the U.S. marine industry with a balanced portfolio across boats, engines and parts and accessories. 5. WWE (WWE) upgraded to Overweight from Equal Weight at Consumer Edge. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Noble Capital to hold a conference » 07:5002/1802/18/20
UAVS, CLBS, CMTL, COCP, CPST, LCTX, XBIO, SPI, ESEA
16th Annual NobleCon…
16th Annual NobleCon Investor Conference will be held in Hollywood, FL on February 16-18.